Injectable antibodies targeting PCSK9 have failed to take off as expected in the cholesterol-lowering market, but Merck & Co hopes to do much better with an oral alternative. MK-0616 has been ...

Investors looking for ways to pump up their passive income streams might want to turn their heads toward the pharmaceutical industry. At recent prices, you can buy shares of Merck (NYSE: MRK) that ...

TD Cowen downgraded Merck & Company Inc (NYSE:MRK) to "Hold" on concerns over uncertainty surrounding Gardasil sales, a slowdown in business development, and the looming loss of exclusivity for ...

Management expects mid-to-high single-digit growth in Merck's total business outside ... pulmonary hypertension indications and the oral PCSK9 inhibitor program targeting hypercholesterolemia.

AZ is now planning to move ahead with a phase 2 programme for its drug, although there’s no doubt it is playing catch-up in the oral PCSK9 inhibitor category with MSD – known as Merck & Co in ...

Both products are witnessing a strong launch. Merck has other promising candidates in its late-stage pipeline, such as MK-0616, an oral PCSK9 inhibitor for hypercholesterolemia, tulisokibart ...

Repatha, an injectable PCSK9 inhibitor from Amgen, grew sales by 36% last year to $2.2 billion. Even if Merck's orally available option goes on to dominate the PCSK9 space, the company needs ...